The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are especially pronounced in those with reduced ejection fraction, a measure of the heart's pumping ability indicative of poor heart functioning, according to new research.
from Diseases and Conditions News -- ScienceDaily https://ift.tt/2HEIZsI
Tuesday 19 March 2019
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment